Step 1: Understanding the Question:
Parameningeal rhabdomyosarcoma is a soft tissue cancer that grows near the meninges, in sites such as the middle ear, nasal cavity and sinuses, or the area near the base of the skull. Because of its location, it can spread into the skull base and even reach the meninges and brain, so choosing the right imaging matters for staging and planning treatment. We need the investigation of choice.
Step 2: Key Concept:
MRI gives far better soft tissue contrast than CT, which makes it the best tool for showing the exact extent of a soft tissue tumor, especially when it may be tracking into the skull base, along cranial nerves, or into the meninges. This detail changes how radiation and surgery are planned.
Step 3: Detailed Explanation:
CECT, contrast enhanced CT, is useful for looking at bone destruction, but it is weaker than MRI at separating tumor from normal soft tissue and does not show meningeal or intracranial extension as clearly, so it falls short as the primary staging tool for a parameningeal site.
CSF cytology can pick up cancer cells if the tumor has already spread into the cerebrospinal fluid, but it is a test for confirming spread once it is suspected, not the main imaging test used to define how far the primary tumor itself extends.
SPECT is a functional nuclear medicine scan more suited to looking at blood flow or metabolic activity in certain conditions, and it does not give the detailed anatomical picture of local tumor extension that is needed here.
MRI, with its excellent soft tissue detail, is the standard way to map how far a parameningeal rhabdomyosarcoma has grown, including any extension toward the meninges or skull base, which is exactly the information needed for staging and treatment planning.
Step 4: Final Answer:
Because of its superior soft tissue and skull base detail, MRI is the investigation of choice for parameningeal rhabdomyosarcoma.